Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC

Despite the promise of immune checkpoint inhibition (ICI), therapeutic responses remain limited. This raises the possibility that standard of care treatments delivered in concert may compromise the tumor response. To address this, we employ tobacco-signature head and neck squamous cell carcinoma mur...

Descripción completa

Detalles Bibliográficos
Autores principales: Saddawi-Konefka, Robert, O’Farrell, Aoife, Faraji, Farhoud, Clubb, Lauren, Allevato, Michael M., Jensen, Shawn M., Yung, Bryan S., Wang, Zhiyong, Wu, Victoria H., Anang, Nana-Ama, Msari, Riyam Al, Schokrpur, Shiruyeh, Pietryga, Ida Franiak, Molinolo, Alfredo A., Mesirov, Jill P., Simon, Aaron B., Fox, Bernard A., Bui, Jack D., Sharabi, Andrew, Cohen, Ezra E. W., Califano, Joseph A., Gutkind, J. Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314425/
https://www.ncbi.nlm.nih.gov/pubmed/35879302
http://dx.doi.org/10.1038/s41467-022-31941-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314425/
https://www.ncbi.nlm.nih.gov/pubmed/35879302
http://dx.doi.org/10.1038/s41467-022-31941-w

Ejemplares similares